Clinical Trial

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2020-02-07; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Status change: Not Yet Recruiting → Recruiting 2020-02-26
Trial Details
NCT Number NCT04262466
Lead Sponsor Immunocore Ltd
Conditions Select Advanced Solid Tumors
Enrollment 410 participants
Start Date 2020-02-25
Primary Completion 2026-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-06